查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1300999

mRNA療法的合同開發和製造市場規模、份額、趨勢分析報告：按應用、按適應症、按最終用途、按地區、細分趨勢，2023-2030年

mRNA Therapeutics Contract Development & Manufacturing Market Size, Share & Trends Analysis Report By Application (Viral Vaccines, Protein Replacement Therapies), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

mRNA 療法合同開發和製造市場的增長和趨勢

Grand View Research, Inc. 的新報告顯示，到 2030 年，全球 mRNA 療法合同開發和製造市場將達到 83.5 億美元。預計

從 2023 年到 2030 年，市場預計將以 10.5% 的複合年增長率擴張。 mRNA 技術和細胞遞送系統的進步，加上其成本效益、易於製造以及針對以前無法治療的途徑的能力，具有徹底改變醫學的無限潛力。mRNA 療法的合同開發和製造 (CDMO) 市場提供了一個利潤豐厚的市場成長機會。

不斷增加的研發投資和強大的 mRNA 療法開發產品線也正在推動市場增長。 例如，根據美國國家醫學圖書館數據庫，截至2021年夏季，美國列出了超過1800項涉及mRNA的臨床研究，其中約四分之一是II期試驗。 近 60% 的候選藥物針對的是實體瘤，30% 是疫苗。 其餘的用於治療自身免疫性疾病、結腸癌、萊姆病等。 此外，mRNA 作為一種潛在的非病毒基因治療遞送方法正在被研究。

此外，為滿足未滿足的醫療需求而開發新的治療藥物正在改變產品市場。 分子復雜性的增加推動了對研究和製造服務和技術的深入了解的需求，以實現新型分子形式的可持續表達和規模化。 生物偶聯、雙特異性抗體生產等平台技術可以顯著縮短開發和生產時間，幫助客戶降低上市時間和投資風險。我們正在尋找熟練的CDMO，他可以 因此，對為製藥和生物技術行業設計和製造產品的 CDMO 的需求急劇增加。

隨著 mRNA 疫苗的引入和傳播，mRNA 技術平台取得了突破，以阻止 2020 年 COVID-19 大流行。 根據 2021 年 10 月發表的一份研究論文，截至 2019 年底，五家專門從事 mRNA 平台的上市公司的總市值為 50 億美元。 截至2021年8月，其市值超過3000億美元。 結果表明，COVID-19 的爆發增加了對 mRNA 的需求。

mRNA 合同開發和製造市場報告亮點

  • 傳染病細分市場佔據主導地位，到 2022 年將佔 100% 的收入份額。
  • 由於存在大量正在研究的腫瘤藥物，代謝和遺傳疾病領域預計將以 11.65% 的複合年增長率增長最快。
  • 由於多種治療病毒感染 (COVID-19) 的疫苗上市，病毒疫苗領域將在 2022 年佔據市場主導地位，銷售額份額將達到 100%。
  • 由於對癌症治療產品開發的日益關注以及 mRNA 在臨床試驗中的良好結果，預計癌症免疫療法在預測期內將出現最大的增長
  • 生物技術公司大力推出新冠肺炎 (COVID-19) 疫苗來抗擊疫情，這將使生物技術公司在 2022 年擁有最高的市場份額，達到 62.56%。
  • 由於支持 mRNA 需求的臨床研究數量不斷增加，政府和學術研究機構領域預計在預測期內復合年增長率為 10.81%。
  • 亞太地區預計在預測期內實現最快的增長率，複合年增長率為 9.1%。 印度和中國等發展中國家的製藥公司和合同製造組織的數量正在大幅增長，因此亞太地區很可能在不久的將來超過歐洲和北美。

內容

第一章調查方法及範圍

  • 市場細分和範圍
  • 市場定義
  • 信息獲取
    • 購買的數據庫
    • GVR 內部數據庫
    • 二手信息和第三方觀點
    • 初步調查
    • 初步調查的詳細信息
  • 信息分析
    • 數據分析模型
  • 市場形成和數據可視化
    • 產品流分析
  • 驗證和發布數據
  • 全球市場複合年增長率計算
  • 輔助信息列表
  • 主要信息列表

第 2 章執行摘要

  • 市場概況
  • 分段快照
  • 衝突注意事項概覽

第三章市場變量、趨勢和範圍

  • 市場血統
    • 母公司市場分析
    • 補充市場分析
  • mRNA 合同開發和製造 (CDMO) 市場 - 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 商業環境工具分析 mRNA 治療藥物合同開發和製造 (CDMO) 市場
    • 波特五力分析
    • 杵分析
  • COVID-19 感染的影響分析

第 4 章 mRNA 治療的合同開發和製造 (CDMO) 市場、按應用進行評估和趨勢分析

  • mRNA 合同開發和製造 (CDMO) 市場，按應用劃分的要點
  • mRNA 治療合同開發和製造 (CDMO) 市場、應用趨勢和市場份額分析，2022 年和 2030 年
  • 病毒疫苗
    • 2020-2030 年病毒疫苗開發市場預估與預測（百萬美元）
  • 蛋白質替代療法
    • 2020-2030 年蛋白質替代療法市場估計和預測（百萬美元）
  • 癌症免疫療法
    • 2020-2030 年癌症免疫治療市場估計和預測（百萬美元）

第五章 mRNA治療藥物合同開發和製造（CDMO）市場適應症的估計和趨勢分析

  • mRNA 合同開發和製造 (CDMO) 市場，按指標劃分的要點
  • 2022 年和 2030 年 mRNA 治療合同開發和製造 (CDMO) 市場、趨勢和市場份額分析
  • 感染
    • 2020-2030 年傳染病市場估計和預測（百萬美元）
  • 代謝和遺傳疾病
    • 2020-2030 年代謝和遺傳疾病市場估計和預測（百萬美元）
  • 心血管疾病和腦血管疾病
    • 2020-2030 年心腦血管疾病市場估算和預測（百萬美元）

第 6 章 mRNA 治療的合同開發和製造 (CDMO) 市場的最終用途估計和趨勢分析

  • mRNA 合同開發和製造 (CDMO) 市場，按最終用途劃分的要點
  • 2022 年和 2030 年 mRNA 治療合同開發和製造 (CDMO) 市場（按最終用途和市場份額分析）
  • 生物科技公司
    • 2020-2030 年創新市場估算和預測（百萬美元）
  • 製藥公司
    • 2020-2030 年製藥公司市場估算和預測（百萬美元）
  • 政府和學術研究機構
    • 政府和學術研究機構 2020-2030 年市場估計和預測（百萬美元）

第 7 章 mRNA 治療合同開發和製造 (CDMO) 市場的區域分析

  • 2022 年和 2030 年 mRNA 療法合同開發和製造 (CDMO) 區域市場份額分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 智利
  • MEA
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第 8 章競爭格局

  • 公司分類
  • 戰略規劃
  • 公司簡介/列表
    • Danaher（Aldevron）
    • Recipharm AB
    • Biomay AG
    • Samsung Biologics
    • Lonza
    • Catalent , Inc.
    • Bio-Indication Inc,
    • eTheRNA
    • Kaneka Eurogentec SA
    • TriLink BioTechnologies
    • ApexBio Technology
    • BioNTech SE.
    • Biocina
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Market Growth & Trends

The global mRNA therapeutics contract development and manufacturing market is expected to reach USD 8.35 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.5% from 2023 to 2030. Advances in mRNA technologies and cellular delivery systems coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways have limitless potential that could revolutionize medicine, representing lucrative growth opportunities for the mRNA therapeutics contract development and manufacturing (CDMO) market.

Increasing investments in R&D for the development of mRNA therapeutics and a strong product pipeline are also propelling the growth of the market. For instance, according to the U.S. National Library of Medicine database, as of summer 2021, over 1,800 clinical studies involving mRNA were listed in the U.S. Approximately one-quarter of which were in phase II. Nearly 60% of candidates target solid tumors, while 30% of candidates are vaccines. The remaining ones are used to treat conditions like autoimmune disorders, colorectal cancer, and Lyme disease. Additionally, mRNA is being researched as a possible nonviral gene therapy delivery method.

In addition, the development of novel therapeutics to address unmet medical needs is altering the market for products. The need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats, is being driven by the rise in molecular complexity. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

With the introduction and widespread usage of mRNA vaccinations to stop the COVID-19 pandemic in 2020, mRNA technology platforms had a breakthrough. At the end of 2019, the combined market capitalization of the five publicly listed firms that specialize in mRNA platforms was USD 5 billion, according to a research paper released in October 2021. That capitalization exceeded USD 300 billion as of August 2021. Consequently, indicating that the COVID-19 outbreak has increased the demand for mRNA.

mRNA Therapeutics Contract Development & Manufacturing Market Report Highlights

  • The infectious diseases segment dominated the market and accounted for the entire revenue share of 100% in 2022, due to the launch of various COVID-19 vaccines that primarily used mRNA
  • The metabolic and genetic diseases segment is anticipated to undergo maximum growth with a CAGR of 11.65%, due to the presence of a strong pipeline under research for cancer therapeutics
  • Viral vaccines segment dominated the market in 2022 and contributed towards the entire revenue share of 100% owing to the availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • Cancer immunotherapies is expected to experience maximum growth over the forecast period due to increased focus to develop products for the treatment of cancer and favorable results presented by mRNA for the same in clinical trials
  • Biotech companies held the highest market share of 62.56% in 2022 due to vigorous efforts by these companies to launch COVID-19 vaccines to control the pandemic
  • The Government & Academic Research Institutes segment is anticipated to witness the fastest CAGR of 10.81% over the forecast owing to the rise in the number of clinical research supporting the demand for mRNA
  • In Asia Pacific, the market is expected to register the fastest growth rate of 9.1% CAGR over the forecast period. Due to the extremely rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1 Commodity flow approach
      • 1.5.1.2. Approach 2 Country wise market estimation using bottom up approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market - Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High adoption of mRNA in vaccines
      • 3.2.1.2. High number of researches in mRNA therapeutics
      • 3.2.1.3. Fundings for mRNA researches
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of research
      • 3.2.2.2. Availability of substitute therapy at low cost.
  • 3.3. Business Environmental Tools Analysis mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Estimates & Trend Analysis

  • 4.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Application Key Takeaways
  • 4.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viral Vaccines
    • 4.3.1. Viral Vaccines Development Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.4. Protein Replacement Therapies
    • 4.4.1. Protein Replacement Therapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.5. Cancer Immunotherapies
    • 4.5.1. Cancer Immunotherapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Estimates & Trend Analysis

  • 5.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Indication Key Takeaways
  • 5.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Infectious Diseases
    • 5.3.1. Infectious Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.4. Metabolic & Genetic Diseases
    • 5.4.1. Metabolic & Genetic Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.5. Cardiovascular & Cerebrovascular Diseases
    • 5.5.1. Cardiovascular & Cerebrovascular Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Estimates & Trend Analysis

  • 6.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By End Use Key Takeaways
  • 6.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Biotech Companies
    • 6.3.1. Innovative Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.4. Pharmaceutical companies
    • 6.4.1. Pharmaceutical companies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Government & Academic Research Institutes Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Regional Analysis

  • 7.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Regional market share analysis, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Market estimates and forecast, 2020 - 2030
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Market estimates and forecast, 2020 - 2030
    • 7.2.3. Canada
      • 7.2.3.1. Canada Market estimates and forecast, 2020 - 2030
  • 7.3. Europe
    • 7.3.1. Europe Market estimates and forecast, 2020 - 2030
    • 7.3.2. UK
      • 7.3.2.1. UK Market estimates and forecast, 2020 - 2030
    • 7.3.3. Germany
      • 7.3.3.1. Germany Market estimates and forecast, 2020 - 2030
    • 7.3.4. France
      • 7.3.4.1. France Market estimates and forecast, 2020 - 2030
    • 7.3.5. Italy
      • 7.3.5.1. Italy Market estimates and forecast, 2020 - 2030
    • 7.3.6. Spain
      • 7.3.6.1. Spain Market estimates and forecast, 2020 - 2030
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Market estimates and forecast, 2020 - 2030
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Market estimates and forecast, 2020 - 2030
    • 7.3.9. Norway
      • 7.3.9.1. Norway Market estimates and forecast, 2020 - 2030
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Market estimates and forecast, 2020 - 2030
    • 7.4.2. Japan
      • 7.4.2.1. Japan Market estimates and forecast, 2020 - 2030
    • 7.4.3. China
      • 7.4.3.1. China Market estimates and forecast, 2020 - 2030
    • 7.4.4. India
      • 7.4.4.1. India Market estimates and forecast, 2020 - 2030
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Market estimates and forecast, 2020 - 2030
    • 7.4.6. Australia
      • 7.4.6.1. Australia Market estimates and forecast, 2020 - 2030
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Market estimates and forecast, 2020 - 2030
    • 7.4.8. South Korea
      • 7.4.8.1. South Korea Market estimates and forecast, 2020 - 2030
  • 7.5. Latin America
    • 7.5.1. Latin America Market estimates and forecast, 2020 - 2030
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Market estimates and forecast, 2020 - 2030
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Market estimates and forecast, 2020 - 2030
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Market estimates and forecast, 2020 - 2030
    • 7.5.5. Colombia
      • 7.5.5.1. Colombia Market estimates and forecast, 2020 - 2030
    • 7.5.6. Chile
      • 7.5.6.1. Chile Market estimates and forecast, 2020 - 2030
  • 7.6. MEA
    • 7.6.1. MEA Market estimates and forecast, 2020 - 2030
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Market estimates and forecast, 2020 - 2030
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Market estimates and forecast, 2020 - 2030
    • 7.6.4. UAE
      • 7.6.4.1. UAE Market estimates and forecast, 2020 - 2030
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Market estimates and forecast, 2020 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Danaher (Aldevron)
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Recipharm AB
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Biomay AG
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Samsung Biologics
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Lonza
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Catalent , Inc.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Bio-Indication Inc,
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. eTheRNA
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Kaneka Eurogentec S.A
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. TriLink BioTechnologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. ApexBio Technology
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. BioNTech SE.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Biocina
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 4 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 5 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 6 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by region, 2020 - 2030 (USD Million)
  • Table 7 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 8 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 9 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 10 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 11 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 12 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 13 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 14 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020-2030, (USD million
  • Table 15 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 16 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 17 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 18 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 19 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 20 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 21 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 22 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 23 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 24 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 25 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 26 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 27 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 28 France mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 29 France mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 30 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 31 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 32 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 33 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 34 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 35 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 36 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 37 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 38 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 39 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 40 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 41 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 42 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 43 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 44 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 45 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 46 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 47 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 48 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 49 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 50 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 51 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 52 China mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 53 China mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 54 China mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 55 India mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 56 India mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 57 India mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 58 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 59 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 60 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 61 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 62 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 63 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 64 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 65 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 66 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 67 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 68 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 69 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 70 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 71 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 72 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 74 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 76 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 78 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 79 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 80 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 81 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 82 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 83 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 84 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 85 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 86 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 87 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 88 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 89 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 90 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 91 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 92 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 93 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 94 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 95 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 96 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)

List of Figures

  • Fig. 1 mRNA therapeutics contract development and manufacturing (CDMO) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 mRNA Therapeutics Contract Development and Manufacturing (CDMO) - Industry value chain analysis
  • Fig. 15 mRNA therapeutics contract development and manufacturing (CDMO) market driver analysis
  • Fig. 16 mRNA therapeutics contract development and manufacturing (CDMO) market restraint analysis
  • Fig. 17 mRNA therapeutics contract development and manufacturing (CDMO) market: Porter's analysis
  • Fig. 18 mRNA therapeutics contract development and manufacturing (CDMO) market: PESTLE analysis
  • Fig. 19 mRNA therapeutics contract development and manufacturing (CDMO) market: application outlook and key takeaways
  • Fig. 20 mRNA therapeutics contract development and manufacturing (CDMO) market: application market share analysis, 2022 - 2030
  • Fig. 21 Global viral vaccines development market, 2020 - 2030 (USD Million)
  • Fig. 22 Global protein replacement therapies market, 2020 - 2030 (USD Million)
  • Fig. 23 Global cancer immunotherapies market, 2020 - 2030 (USD Million)
  • Fig. 24 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication outlook and key takeaways
  • Fig. 25 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication market share analysis, 2022 - 2030
  • Fig. 26 Global infectious diseases market, 2020 - 2030 (USD Million)
  • Fig. 27 Global metabolic & genetic diseases market, 2020 - 2030 (USD Million)
  • Fig. 28 Global cardiovascular and cerebrovascular diseases market, 2020 - 2030 (USD Million)
  • Fig. 29 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user outlook and key takeaways
  • Fig. 30 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user market share analysis, 2022 - 2030
  • Fig. 31 Global biotech companies market, 2020 - 2030 (USD Million)
  • Fig. 32 Global pharmaceutical companies market, 2020 - 2030 (USD Million)
  • Fig. 33 Global government & academic research institutes market, 2020 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, 2020 - 2030 (USD Million)
  • Fig. 41 Europe mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 42 Germany key country dynamics
  • Fig. 43 Germany mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 58 Asia-Pacific mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 59 Japan key country dynamics
  • Fig. 60 Japan mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 65 Australia key country dynamics
  • Fig. 66 Australia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 71 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 72 Brazil key country dynamics
  • Fig. 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 74 Mexico key country dynamics
  • Fig. 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 78 MEA mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 87 Key company categorization
  • Fig. 88 Company market positioning
  • Fig. 89 Market participant categorization
  • Fig. 90 Strategy framework